Related Experiment Videos
T cells and B cells in chronic renal failure
B Descamps-Latscha1, L Chatenoud
1Nephrology Department, INSERM, Hôpital Necker, Paris, France.
Seminars in Nephrology
|May 1, 1996
Summary
Immune cell abnormalities in end-stage renal disease (ESRD) worsen with disease progression and dialysis. Research explores strategies to improve immune response in uremic patients, particularly for hepatitis B virus vaccination.
Area of Science:
- Immunology
- Nephrology
- Pathophysiology
Background:
- End-stage renal disease (ESRD) is characterized by significant immune abnormalities.
- Current renal replacement therapies, including hemodialysis, have not improved the immune status of uremic patients.
- Understanding immune dysregulation in ESRD is crucial for developing effective treatments.
Purpose of the Study:
- To review the role of T cells and B cells in normal immunity.
- To present functional and phenotypic abnormalities of T and B cells in uremic patients.
- To investigate early-stage immune abnormalities in chronic renal failure and their progression.
Main Methods:
- Review of existing literature on immune responses in ESRD.
- Analysis of functional and phenotypic characteristics of T and B cells in uremic patients.
- Evaluation of the impact of dialysis on immune cell function.
Main Results:
- Immune abnormalities in ESRD are present early in chronic renal failure and worsen with uremia.
- Hemodialysis exacerbates these immune dysfunctions.
- Abnormalities impact patient response to vaccinations, such as for hepatitis B virus.
Conclusions:
- ESRD involves complex immune dysregulation affecting T and B cells.
- Dialysis procedures can worsen immune deficits in uremic patients.
- Further research into T helper cell subpopulations (Th1/Th2) may guide immunointervention strategies for ESRD.